Clinical Trial Update: Study of Urinary Kallikrein to Enhance Collateral Circulation in Symptomatic Intracranial Atherosclerosis [Phase 4]

View source ↗

Summary

Phase 4 clinical trial investigating urinary kallikrein to enhance collateral circulation in symptomatic intracranial atherosclerosis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anterior Cerebral Circulation Infarction
• Collateral Circulation
• Intracranial Arteriosclerosis

Drugs mentioned

• urinary kallikrein (urinary kallikrein)

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Intracranial Arteriosclerosis, Collateral Circulation | Phase 4 | Status: WITHDRAWN